EMA Authorised: Maviret (glecaprevir;pibrentasvir) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The European Medicines Agency authorised Maviret (glecaprevir/pibrentasvir) for chronic hepatitis C, with AbbVie Deutschland GmbH & Co. KG as the marketing auth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Maviret (glecaprevir/pibrentasvir)

Snippet

Status: Authorised. Therapeutic area: Hepatitis C, Chronic. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 02/03/2023. Accelerated assessment